# Aspen Neuroscience funding rounds and investors

As of 14 Oct 2026, Aspen Neuroscience has raised $115M across 1 verified round on record; latest: $115 million Series C led by Arch Venture Partners, Frazier Life Sciences and 2 others, announced 20 Nov 2025.

Aspen Neuroscience develops personalized regenerative therapies, specifically autologous iPSC-derived cell replacement therapies for Parkinson's disease.

Website: https://aspenneuroscience.com  
Headquarters: San Diego  
Page: https://fireround.dev/companies/aspenneuroscience.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-11-20 | Series C | $115 million | Arch Venture Partners, Frazier Life Sciences, OrbiMed, Revelation Partners | Axon, Balyasny Asset Management, Cormorant Asset Management, Kite, a Gilead Company, Lifeforce Capital, Lyfe Capital, Medical Excellence Capital, Prebys Ventures, S32 | [prnewswire.com](https://www.prnewswire.com/news-releases/aspen-neuroscience-announces-115-million-series-c-financing-to-accelerate-personalized-cell-therapy-programs-302621124.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.